Kornimate/medical-research-clean huggingface dataset:
0.05 versus 0.1 mg spinal morphine for reducing morphine requirement after vaginal hysterectomy

Conditions: Pain; Vaginal Hysterectomy

Summary: this study aims to compare the efficacy of 0.05 mg and 0.1 mg spinal morphine in reducing postoperative morphine requirement in patients undergoing vaginal hysterectomy with/without anterior and posterior vaginoplasty.


Eligibility criteria:
inclusion criteria: * female asa physical status 1-3 * undergoing vaginal hysterectomy with/without anterior and posterior vaginoplasty * be able to operate patient-controlled analgesia (pca) exclusion criteria: * allergy to the study drugs * history of bleeding tendency * infection at the back * refuse to spinal anesthesia * history of cad or cva

Keywords: spinal morphine 0.05 mg spinal morphine
study of denosumab in the treatment of hypercalcemia of malignancy in subjects with elevated serum calcium

Conditions: Breast Cancer; Hypercalcemia of Malignancy; Colon Cancer; Endocrine Cancer; Head and Neck Cancer; Kidney Cancer; Lung Cancer; Lymphoma; Metastatic Cancer; Multiple Myeloma; Parathyroid Neoplasms; Renal Cancer; Thyroid Cancer; Hodgkin's Lymphoma; Non-Hodgkin's Lymphoma; Non-Small Cell Lung Cancer

Summary: the purpose of this study is to determine the potential of denosumab to treat hypercalcemia of malignancy in patients with elevated serum calcium who do not respond to recent treatment with intravenous bisphosphonates by lowering corrected serum calcium \</= 11.5 mg/dl (2.9 millimoles /l) by day 10.


Eligibility criteria:
inclusion criteria: * hypercalcemia of malignancy (hcm) as defined as documented histologically or cytologically confirmed cancer and a corrected serum calcium (csc) \> 12.5 mg/dl (3.1 millimoles /l) at screening by local laboratory * last iv bisphosphonate treatment must be \>/= to 7 days and \</= to 30 days before the screening corrected serum calcium * adults (\>/=18 years) * adequate organ function as defined by the following criteria: * serum aspartate aminotransferase (ast) \</= 5 x upper limit of normal (uln) * serum alanine aminotransferase (alt) \</= 5 x upper limit of normal * serum total bilirubin \</= 2 x upper limit of normal exclusion criteria: * evidence of benign hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin d intoxication, milk alkali syndrome, sarcoidosis, or other granulomatous disease * receiving dialysis for renal failure * treatment with thiazides, calcitonin, mithramycin, or gallium nitrate within their window of expected therapeutic effect (as determined by the physician) prior to the date of the screening csc * treatment with cinacalcet within 4 weeks prior to the date of the screening csc * thirty days or less since receiving an investigational product (other than denosumab) or device (ie, does not have marketing authorization; thalidomide use is allowed) in another clinical study * known sensitivity to any of the products to be administered during the study (eg, mammalian derived products) * female subject is pregnant or breast feeding, or planning to become pregnant within 7 months after the end of treatment * female subject of childbearing potential is not willing to use 2 highly effective methods of contraception during treatment and for 7 months after the end of treatment * subject will not be available for follow-up assessment. * any organic or psychiatric disorder that, in the opinion of the investigator, might prevent the subject from completing the study or interfere with the interpretation of the study results

Keywords: hypercalcemia calcium bisphosphonates denosumab amgen malignancy 20070315 hmc oncology hematology
the effect of manipulation of the cervical spine on pain biomarkers

Conditions: Neck Pain, Posterior

Summary: this study evaluates the effect of high-velocity low-amplitude thrust (hvlat) manipulation to the cervical spine on neuropeptide expression as determined by the plasma concentration of oxytocin, neurotensin, orexin a and cortisol; and examine the effect of hvlat manipulation on pain perception in symptomatic females with non-specific mechanical cervical spine pain

a high-velocity low-amplitude thrust (hvlat) manipulation or commonly known as a spinal manipulation, is an intervention frequently used by physical therapists and other healthcare practitioners as an alternative treatment to help relieve spinal pain the mechanism by which hvlat manipulation modulates pain remains undefined, although this does not contradict the clinical effects from hvlat manipulation. furthermore, there is evidence that suggests analgesia after hvlat manipulation. there is a variety of observed and proposed phenomena that can explain the mechanisms for the psychological, mechanical, or neurophysiological responses from a hvlat manipulation associated with alterations in pain processing or sympathetic and motor systems' excitation.

Eligibility criteria:
inclusion criteria: * 20 - 45 years of age * a score of 10 or more out of 50 on the neck disability index (ndi) questionnaire * symptoms of pain present for 30 days or less and no pain symptoms below your shoulder exclusion criteria: * serious condition (such as cancer, spondylolisthesis, rheumatoid arthritis, or ankylosing spondylitis) * cervical spinal stenosis signs (such as incoordination in hands, arms and legs, inability of walking at a brisk pace, or bowel and bladder incontinence) * nerve root compression (such as changes in sensation, muscle weakness, or decreased reflexes) * works the night shift * steroid medication within 3 months * pregnancy or postpartum * pending legal action regarding their neck pain * history of whiplash associated disorder and/or cervical spine surgery
a case series comparing t+lrti to partial trapeziectomy for thumb osteoarthritis

Conditions: Arthritis; Health Related Quality of Life; Osteoarthritis

Summary: the purpose of this study was to measure the differences in health related quality of life (hrqol) and functional measurements between two groups of patients with carpometacarpal osteoarthritis of the thumb.

two patient groups, who have been diagnosed with carpometacarpal osteoarthritis of the thumb were compared to measure the health related quality of life (hrqol) and functional outcomes following two different surgical procedures. the first procedure is currently the most used procedure is north america, trapeziectomy with ligament reconstruction and tendon interposition (t+lrti); this procedure is compared to partial trapeziectomy and tendon interposition (pt+ti). hrqol is measured using three questionnaires: one generic, one condition specific and one to measure utility (costs). patients received their procedures from the respective surgeons and then came in for regular follow up at 1, 3, 6 and 12 months. at these follow up visits the questionnaires and functional measurements (including grip, key pinch and tip pinch strength), were completed

Eligibility criteria:
inclusion criteria: * diagnosis of advanced stage (eaton stages ii-iv) carpometacarpal joint (cmcj) osteoarthritis (oa of the thumb * willingness to undergo surgery for cmcj oa; * over the age of 18; * able to provide informed consent; and * ability to read and comprehend english to complete the hrqol questionnaires exclusion criteria: * 1) diagnosis of eaton stage i cmcj oa of the thumb \[17\]; 2) under the age of 18; 3) presence of any concomitant hand pathology (including rheumatoid arthritis, neuropathy and traumatic arthritis); and 4) previous surgery on the same hand or currently under consideration for other unrelated hand surgery

Keywords: partial trapeziectomy tendon interposition trapeziectomy thumb carpometacarpal joint
safety and efficacy of 3 dose levels of nmd670 in adult patients with myasthenia gravis

Conditions: Myasthenia Gravis; Myasthenia Gravis, MuSK

Summary: this phase 2 proof-of-concept, dose range finding study aims to evaluate the safety and efficacy of 3 dose levels of nmd670 vs placebo in adult patients with mg with antibodies against achr or musk, administered twice a day (bid) for 21 days.


Eligibility criteria:
inclusion criteria: * participant must be a male or female being 18 or more, at the time of signing the informed consent * diagnosis of mg, mgfa class ii, iii or iv * documented positive achr or musk antibody test. * participant must be able to swallow tablets * body mass index between 18 and 35 kg/m2, inclusive, at screening, and with a minimum weight of 40 kg * contraceptive use by men and women must be consistent with local regulations regarding the methods of contraception for those participating in clinical studies * participant is capable of and has given signed informed consent exclusion criteria: * known medical or psychological condition(s) or risk factor that, in the opinion of the investigator, might interfere with the patient's full participation in the study, pose any additional risk for the patient, or confound the assessment of the patient or outcome of the study * participants with other significant clinical and/or laboratory safety findings that may interfere with the conduction or interpretation of the study * participants that received treatment with an investigational medical product within 30 days or 5 half-lives of the medication, whichever is longer prior to day 1 * participants with history of poor compliance with relevant mg therapy * female patients who plan to become pregnant during the study or are currently pregnant or breastfeeding
risk factors for medium-term adverse outcomes and predictive modeling for breast cancer patients

Conditions: Breast Cancer

Summary: this subproject is included in a project coordinated between program groups evaluation of health services of epidemiology and public health (project camiss). the overall objective is to evaluate different aspects of health care received by patients with breast cancer from the diagnostic process, treatment, complications, survival and quality of life, to provide information to improve the effectiveness of interventions, reduce variability, have best predictive rules and increase the quality of life. the main objective of the subproject is to create and validate prospectively predictive rules of recurrence, complications, mortality, changes in quality of life in these patients at admission and one/two years of treatment and to evaluate the external validity of our rules to predict relapses, complications and mortality in the retrospective sample of patients participating in screening programs. observational methodology with information available from a retrospective cohort of women diagnosed between 2000 and 2009 and another 2-year prospective follow-up included 2040 incident cases of breast cancer in 18 hospitals of 5 regions. cohorts will learn clinical and health care diagnosis, tumor, treatment, hospital, follow-up (complications, relapse, and vital status) cost and quality of life. prediction rules are created by means of regression/cox models at the prospective sample and also investigators will assess the external validity in the retrospective cohort in the case of recurrence, complications and mortality. expected results: there are currently no results of cohort analysis of the diagnostic process of care that integrates different aspects. the study will create tools to assist prognostic and therapeutic decision making process in these patients


Eligibility criteria:
inclusion criteria: * women over the age of 18 with both incidental in situ and infiltrating breast cancer. exclusion criteria: * lymphoma, sarcoma, lobular carcinoma in situ and inflammatory carcinoma of the breast are excluded
comparison of 7-day and 14-day bismuth based quadruple therapy for secondary helicobacter pylori eradication

Conditions: Helicobacter Infection

Summary: at present, triple therapy are recommended by various guidelines for the treatment of helicobacter pylori (h. pylori) infection. recent studies have shown worldwide high treatment failure rates with one week first line clarithromycin based triple therapy necessitating salvage strategy to eradicate h. pylori in primary treatment failure. however, the exact duration of bismuth based second line treatment is not determined. therefore, the investigators performed this study to evaluate the eradication rate of 1 or 2-week quadruple regimen as a second-line therapy.


Eligibility criteria:
inclusion criteria: * h. pylori infection * aged between 18-80 years * are willing to received eradication therapy for h. pylori exclusion criteria: * children and teenagers aged less than 18 years or over 80 years * previous eradication therapy for h. pylori * history of gastrectomy * previous allergic reaction to antibiotics * use of prompt pump inhibitors and antibiotics in the recent 4 weeks * active upper gi bleeding in the recent 1 week * contraindication to treatment drugs * pregnant or lactating women * severe concurrent disease or malignancy

Keywords: helicobacter pylori bismuth salvage treatment metronidazole
oligonucleotide ligation assay (ola) resistance study

Conditions: HIV Positive

Summary: the investigators propose to gauge improvements in the rate of durable suppression of viral replication by art when ola is used to guide clinical decisions at the pepfar coptic hope center in kenya, and to determine the cost-effectiveness of implementing this strategy at coptic hope center.

durable suppression of hiv replication is critical to (1) improving the health of infected individuals, (2) to reducing hiv transmission to sexual partners and from mothers to their infants, and (3) to maintaining the effectiveness of the current 1st-line non-nucleoside reverse transcriptase inhibitors (nnrti)- based art. across multiple trials, individuals with nnrti-resistance, even at low-concentrations, have substantially greater virologic failure when treated with nvp- vs pi-art. a cost-effective strategy is needed to detect and manage arv-resistant hiv infections. a simple low-cost innovative assay the investigators developed and successfully transferred to asian and african countries (oligonucleotide ligation assay (ola)) can detect nnrti+lamivudine (3tc) resistant hiv using reagents that costs \<$7.00/person. furthermore, detection of nnrti-resistance by ola is highly (p\<0.001) associated with virologic failure of nevirapine (nvp)-art in two retrospective studies; one of thai women who had been previously randomized to single-dose nvp and the second of arv-naïve kenyan adults. the investigators hypothesize that implementation of ola into routine care will allow kenyan clinicians to appropriately target protease inhibitor (pi)-based art and improve rates of durable suppression of viral replication, and thus improve cd4 cell gains and individuals' health, reduce the transmission of arv-resistant hiv within the community, and maintain the utility of nnrti-art. in addition, the investigators hypothesize that programmatically ola-guided art will be more cost-efficient compared to the current strategy of empiric use of nnrti-art as initial treatment.

Eligibility criteria:
inclusion criteria: 1. confirmed hiv infection 2. \>2 years of age 3. qualifying for 1st-line art based on kenyan guidelines 4. plan to reside in area for \>1 year 5. adult patient or parent of minor agrees to study and provides informed consent exclusion criteria: 1. received art previously from hope center 2. ongoing art 3. plan to start 2nd-line art

Keywords: transmitted drug resistance
clinical study of hmpl-653 in treatment of advanced malignant solid tumors and tgct

Conditions: Advanced Malignant Solid Tumors; TGCT

Summary: to evaluate the safety and tolerability of hmpl-653 in patients with advanced solid tumors who have failure of standard of care or can not tolerate standard of care or those with tgct, and to determine the maximum tolerated dose (mtd) and/or the recommended phase ii clinical study dose (rp2d) of hmpl-653 in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. able to understand and willing to sign the icf. 2. aged 18 to 75 years. 3. eastern cooperative oncology group (ecog) performance status of 0 or 1. 4. life expectancy at least 12 weeks. 5. adequate bone marrow, liver and kidney function. exclusion criteria: 1. toxicity associated with previous antitumor therapy not recovered to ≤ctcae grade 1； 2. previous treatment with anti-csf1r therapy and have progressive disease; 3. receiving approved systematic antitumor therapy or in the treatment period of other interventional clinical study within 4 weeks prior to the first dose. 4. patients with central nervous system (cns) malignant tumor or malignant solid tumor with known cns metastasis; 5. pregnant or lactating women.
product performance of a daily disposable contact lens

Conditions: Myopia

Summary: the objective of this one week, single group, bilateral, open-label study is to evaluate the product performance of the bausch \& lomb daily disposable cosmetic tint contact lens (test) when worn on a daily disposable basis by adapted current wearers of a marketed opaque tinted soft contact lens.


Eligibility criteria:
inclusion criteria: * subjects must be females of chinese descent and of legal age and no older than 38. or subjects that are females of chinese descent and are at least 15 years of age and less than the legal age must: have a parent/legal guardian provide informed consent. * subjects must have clear central corneas and be free of any anterior segment disorders. * subjects must be adapted current wearers of marketed opaque tinted soft contact lenses, wear their lenses two days or more per week, and wear a lens in each eye. exclusion criteria: * subjects who have worn gas permeable (gp) contact lenses within the last 30 days or have worn polymethylmethacrylate (pmma) lenses within the last three months. * subjects who have any systemic disease affecting ocular health. * subjects using any systemic or topical medications that will, in the investigator's opinion, affect ocular physiology or lens performance. * subjects with an active ocular disease or are using any ocular medication. * subjects with any scar or neovascularization within the central 4 mm of the cornea. * subjects who are aphakic or amblyopic. * subjects who have had any corneal surgery (eg, refractive surgery). * subjects who currently wear monovision, multifocal, or toric contact lenses.

Keywords: contact lens
hypofractionated external-beam radiotherapy for intact cervical cancer (heroicc-trial): a feasibility study

Conditions: Cervical Cancer

Summary: external radiation given in 25 fractions or so together with weekly chemotherapy and followed by 3 or 4 fractions of brachytherapy is the standard of care for patients with locally advanced cervical cancer. this study investigates the role of shortened external radiotherapy regimen (hypofractionated radiotherapy) by randomizing patients to this experimental regimen versus the standard of care.the purpose of this study is to access the feasibility of patient accrual to this trial in the canadian setting and to provide an initial evaluation of cancer response and treatment tolerability.


Eligibility criteria:
inclusion criteria: * age 18 years or older * international federation of gynecology and obstetrics (figo) ia or ib1 cervical cancers if not surgical candidates, but amenable to definitive chemoradiotherapy as proposed in this trial. * figo stage ib2, ib3, iia or iib cervical cancers * figo stage iiic1 cervical cancers are candidates but must meet all the following criteria: 1. largest node is less than 3 cm 2. less than 3 pathological nodes 3. no nodes located in the common iliac chain. 4. cervical confined or with parametrial invasion * histologically-confirmed invasive uterine cervical carcinoma of subtypes squamous cell, adenocarcinoma or adenosquamous cell * candidate for definitive chemoradiotherapy to be delivered with weekly cisplatin * brachytherapy candidate exclusion criteria: * figo stage iiia, iiib, iiic2, iva or ivb * figo stage iiic1 with node greater than 3 cm, common iliac node or greater than 2 pathological nodes * previous pelvic or abdominal radiotherapy * patients requiring paraaortic nodal irradiation * inflammatory bowel disease * connective tissue disorder (eg. scleroderma, systemic lupus erythematous) * neuroendocrine, glassy cell, small cell, adenoid cystic carcinoma, adenoid basal carcinoma, clear cell, serous, endometrioid, verrucous carcinoma, melanoma, and sarcoma histologies * patient unable to undergo mr scan * eastern cooperative oncology group (ecog) performance status greater than 3 * not a cisplatin candidate

Keywords: hypofractionated external-beam radiotherapy
differential influences of integral and incidental emotion on cancer-related judgments and decision making

Conditions: Cancer; Overweight; Obesity

Summary: background: researchers are testing new methods for research projects. they want to see how people respond to different types of communication, including videos. they also want to learn how people respond to life events and how they pay attention to computer tasks. they want to learn about how various risks and threats affect the way people make decisions. objectives: to learn how different stimuli and events affect the way people make decisions. eligibility: adults ages 18 and older with a u.s. computer address design: participants will be recruited online. participants will take one of three studies online. each study will take about a half hour. participants in study 1 will watch a short video from a popular movie then answer questions. they will also complete 2 questionnaires. one will be about how likely they think it is that they will experience different risks and threats. the other will be about goals for behavior change. participants in study 2 will write in detail about a life event. then they will answer questions. they will also complete the same 2 questionnaires as study 1. participants in study 3 will pay close attention to words and images on a computer. they will answer questions about attitudes toward different behaviors, products, and experiences. ...

despite evidence that both integral (i.e., related to the decision) and incidental (i.e., unrelated to the decision) emotions influence cancer-related decision making, no research has systematically examined whether these two types of emotion generate similar patterns of influence, as predicted by decision-making models. this is important because incidental emotions are often used experimentally to draw causal conclusions about how emotions influence cancer-related decisions with the notion that results will generalize to produce knowledge about integral emotions as well. across three studies, we plan to directly compare integral and incidental emotional influences on judgments and decisions related to cancer control. we plan to examine whether effects are contingent on the type of emotional influence (the discrete emotions anger and fear, or general positive affect) or type of emotion induction (video, autobiographical induction, or evaluative conditioning). across experiments, we predict that emotion will influence both judgment and decision-making outcomes when the induced emotion is integral as well as when it is incidental. however, we predict that the magnitude of the effect of emotion on these types of responses will be significantly greater when emotions are integral to a judgment or decision, compared to when emotions are incidental.

Eligibility criteria:
* inclusion criteria: adults ages 18 and older with a u.s. computer address

Keywords: emotion judgment decision making
gutme!: ibs and collagen protein powder an interventional study

Conditions: Irritable Bowel Syndrome; Irritable Bowel; Irrit

Summary: in this study we would like to understand how or if a food-based supplement affects gut symptoms such as bloating, stomach cramps and irregular bowel habits. through using a digital symptom tracking app for a few weeks, you may just learn more about exactly what is triggering your symptoms!


Eligibility criteria:
inclusion criteria: * us based * self report bloating exclusion criteria: * vegan or vegetarian diet * suffering from any skin disorders * kidney disease * treated medical issues * glutamine sensitivity